{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T02:50:52Z","timestamp":1794538252899,"version":"4.9.1"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eNeurologicalSci"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ensci.2025.100567","type":"journal-article","created":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T22:48:50Z","timestamp":1747003730000},"page":"100567","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Effects of immunotherapy on isolated optic neuritis associated with ozoralizumab, a novel anti-tumor necrosis factor \u03b1 NANOBODY\u00ae compound: A case report"],"prefix":"10.1016","volume":"39","author":[{"given":"Masato","family":"Okitsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keizo","family":"Sugaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Shiotani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ensci.2025.100567_bb0005","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000992","article-title":"Demyelinating events following initiation of anti-TNF\u03b1 therapy in the British Society for Rheumatology Biologics Registry in Rheumatoid Arthritis","volume":"8","author":"Taylor","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.ensci.2025.100567_bb0010","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.3390\/jcm12041630","article-title":"Past, present and (foreseeable) future of biological anti-TNF alpha therapy","volume":"12","author":"Leone","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ensci.2025.100567_bb0015","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.853008","article-title":"Ozoralizumab, a humanized anti-TNFalpha NANOBODY compound, exhibits efficacy not only at the onset of arthritis in a human TNF transgenic mouse but also during secondary failure of administration of an anti-TNFalpha IgG","volume":"13","author":"Ishiwatari-Ogata","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ensci.2025.100567_bb0020","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1007\/s10067-020-05004-8","article-title":"Prevalence of Sj\u00f6gren's syndrome associated with rheumatoid arthritis in the USA: an observational study from the corrona registry","volume":"39","author":"Harrold","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.ensci.2025.100567_bb0025","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/archneurol.2007.17","article-title":"Weinshenker neuromyelitis optica and non organ-specific autoimmunity","volume":"65","author":"Pittock","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ensci.2025.100567_bb0030","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/ard.2006.066787","article-title":"Optic neuritis occurring with anti-tumour necrosis factor alpha therapy","volume":"66","author":"Simsek","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ensci.2025.100567_bb0035","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1001\/jamaneurol.2024.3524","article-title":"Risk of inflammatory central nervous system diseases after tumor necrosis factor-inhibitor treatment for autoimmune diseases: a systematic review and meta-analysis","volume":"81","author":"Xie","year":"2024","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ensci.2025.100567_bb0040","doi-asserted-by":"crossref","first-page":"18102","DOI":"10.1038\/s41598-022-23152-6","article-title":"A novel anti-TNF-\u03b1 drug ozoralizumab rapidly distributes to inflamed joint tissues in a mouse model of collagen induced arthritis","volume":"12","author":"Oyama","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ensci.2025.100567_bb0045","doi-asserted-by":"crossref","first-page":"5994","DOI":"10.3390\/ijms24065994","article-title":"NANOBODIES\u00ae: a review of diagnostic and therapeutic applications","volume":"24","author":"Jin","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ensci.2025.100567_bb0050","doi-asserted-by":"crossref","first-page":"1149874","DOI":"10.3389\/fimmu.2023.1149874","article-title":"Unique structure of ozoralizumab, a trivalent anti-TNF\u03b1 NANOBODY\u00ae compound, offers the potential advantage of mitigating the risk of immune complex-induced inflammation","volume":"14","author":"Kyuuma","year":"2023","journal-title":"Front. Immunol."}],"container-title":["eNeurologicalSci"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405650225000218?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405650225000218?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T09:46:33Z","timestamp":1748425593000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405650225000218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":10,"alternative-id":["S2405650225000218"],"URL":"https:\/\/doi.org\/10.1016\/j.ensci.2025.100567","relation":{},"ISSN":["2405-6502"],"issn-type":[{"value":"2405-6502","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of immunotherapy on isolated optic neuritis associated with ozoralizumab, a novel anti-tumor necrosis factor \u03b1 NANOBODY\u00ae compound: A case report","name":"articletitle","label":"Article Title"},{"value":"eNeurologicalSci","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ensci.2025.100567","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100567"}}